Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 3.
doi: 10.1111/bjh.70239. Online ahead of print.

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

M R Seefat  1 , D G J Cucchi  1 , L van Boven  2 , N Durdu-Rayman  3 , K Groen  1 , M-D Levin  4 , K de Heer  1   5 , B de Valk  6 , R Wester  7 , E van der Spek  8 , R Rentenaar  1 , C L B M Korst  1 , M Quik  1 , C A O'Neill  1 , P Tzortzi  1 , F Smits  1   9 , R Mathot  3 , M R Heerma van Voss  1 , N W C J van de Donk  1 , T Mutis  1 , I H Bartelink  3 , S Zweegman  1
Affiliations

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

M R Seefat et al. Br J Haematol. .

Abstract

Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate-day dosing was less effective.

Keywords: Dosing; Multiple myeloma; Pharmacodynamic; Pharmacokinetic; Pomalidomide.

PubMed Disclaimer

References

REFERENCES

    1. Dhakal B, He J, Schecter JM, Deraedt W, Slaughter A, Lonardi C, et al. Real‐world treatment patterns and outcomes in patients with lenalidomide‐refractory multiple myeloma with 1 to 3 prior lines: SEER‐Medicare database. Clin Lymphoma Myeloma Leuk. 2025;25:e394–e403.
    1. Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, et al. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: a pooled analysis. Eur J Haematol. 2017;99(3):199–206.
    1. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low‐dose dexamethasone versus high‐dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM‐003): a randomised; open‐label; phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
    1. Zander T, Aebi S, Pabst T, Renner C, Driessen C. Spotlight on pomalidomide: could less be more? Leukemia. 2017;31(9):1987–1989.
    1. Zander T, Pabst T, Schar S, Aebi S, Mey U, Novak U, et al. Alternate‐day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter; single‐arm phase 2 trial. Leukemia. 2023;37(3):699–701.

LinkOut - more resources